1. Home
  2. FRBA vs BWAY Comparison

FRBA vs BWAY Comparison

Compare FRBA & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bank

FRBA

First Bank

HOLD

Current Price

$17.28

Market Cap

377.6M

Sector

Finance

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$25.14

Market Cap

450.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRBA
BWAY
Founded
2007
2003
Country
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
377.6M
450.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FRBA
BWAY
Price
$17.28
$25.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$19.00
$26.50
AVG Volume (30 Days)
70.7K
99.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.08%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.06
$314.08
Revenue Next Year
$5.86
$23.37
P/E Ratio
$9.97
$75.68
Revenue Growth
N/A
N/A
52 Week Low
$12.74
$7.84
52 Week High
$18.11
$25.65

Technical Indicators

Market Signals
Indicator
FRBA
BWAY
Relative Strength Index (RSI) 59.77 62.94
Support Level $17.02 $22.50
Resistance Level $17.52 $24.15
Average True Range (ATR) 0.44 1.51
MACD 0.04 -0.06
Stochastic Oscillator 85.61 91.71

Price Performance

Historical Comparison
FRBA
BWAY

About FRBA First Bank

First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of businesses. Its services are Business Banking; Personal banking; Digital Banking; and Lending.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: